
Opinion|Videos|January 24, 2025
Key Strategies for Preventing CRS and ICANS
Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell lymphomas.
Advertisement
Video content above is prompted by the following:
What are your key strategies for preventing CRS and ICANS in patients receiving bispecific therapies for B-cell lymphomas?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5